Prevencio Receives FDA Breakthrough Device Designation for HART CADhs, Its Artificial Intelligence-driven Blood Test for Obstructive Coronary Artery Disease
KIRKLAND, Wash.--(BUSINESS WIRE)-- Prevencio, Inc., the leader in artificial intelligence-powered blood tests for cardiovascular diagnostics, announces that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its HART CADhs® test. This designation recognizes HART CADhs as an innovative technology for identifying obstructive coronary artery disease (CAD) —a condition responsible for significant morbidity and mortality. The designation is reserved for technologies that offer significant advantages over existing solutions and address unmet medical needs.
HART CADhs is the only AI-based multi-protein blood test capable of accurately detecting blockage in the heart's arteries. By combining multiple cardiac proteins with proprietary machine learning algorithms, HART CADhs delivers actionable insight through a simple, non-invasive blood draw, bridging critical diagnostic gaps in current cardiovascular care.
'The FDA's Breakthrough Device Designation is a pivotal milestone in our mission to revolutionize the diagnosis and treatment of obstructive coronary artery disease,' said Rhonda Rhyne, President and Chief Executive Officer of Prevencio. 'We are committed to expanding the use of HART CADhs from outpatient settings into emergency care environments to ensure that patients receive earlier, more accurate, and potentially life-saving diagnoses.'
HART CADhs is currently available as a Lab Developed Test (LDT) with a 2 to 10-day turnaround, making it ideal for evaluating stable, non-urgent patients. The Breakthrough Device Designation enables close collaboration with the FDA and an expedited review process, supporting Prevencio's goal to advance the test into a rapid, FDA-cleared in vitro diagnostic (IVD) with a one-hour result time —ideal for evaluating chest pain patients in emergency rooms.
HART CADhs was developed using Prevencio's proprietary HART platform in collaboration with researchers at Massachusetts General Hospital (MGH). In clinical research, the test demonstrated high accuracy (0.86 AUC) in detecting obstructive CAD, significantly outperforming standard-of-care tests such as stress echocardiography and nuclear imaging, which yielded only 0.52 AUC.
'With nearly half of U.S. counties lacking access to a cardiologist and long wait times in urban centers, a simple, accurate blood test to diagnose obstructive CAD offers tremendous potential to improve access to early diagnosis and intervention,' said James L. Januzzi, MD, a practicing cardiologist at MGH, Professor of Medicine at Harvard Medical School, Chief Scientific Officer at the Baim Institute for Clinical Research and Principal Investigator for the HART test development and validation. 'Our studies show HART CADhs is informative in a broad range of patient types including those with acute symptoms as well as those not diagnosed with a heart attack yet may have dangerous arterial obstruction. This suggests usefulness in both acute and outpatient settings.'
Cardiovascular disease remains the leading cause of death in the United States and worldwide. According to the American Heart Association, cardiovascular disease and stroke account for over $318 billion in annual U.S. healthcare costs, nearly 10% of total healthcare spending. Prevencio's HART blood tests are designed to improve patient outcomes and reduce costs through earlier, more accurate, and more accessible diagnostics.
In addition to HART CADhs, Prevencio also offers HART CVE®, a second AI-driven, multi-protein blood test that assesses a patient's one-year risk of heart attack, stroke, or cardiovascular death. Both tests are currently available to healthcare providers.
About Prevencio HART Tests: Powered by AI, Prevencio is revolutionizing cardiac diagnostics with AI-driven blood tests for cardiovascular disease and custom diagnostics for diagnostic, medical device and pharmaceutical companies. Using this novel approach, the company has developed seven blood tests that significantly improve diagnosis and risk assessment for a variety of heart and blood vessel-related complications.
HART test results have been peer-reviewed published 35 times, including at leading cardiovascular meetings—(European Society of Cardiology Congress; American College of Cardiology Scientific Sessions; American Heart Association Scientific Sessions; American Diabetes Association Scientific Sessions; and Transcatheter Cardiovascular Therapeutics Sessions) and in top-tier journals—(Journal of American College of Cardiology; American Journal of Cardiology; Clinical Cardiology; Biomarkers in Medicine; Journal of American Heart Association; and European Journal of Preventive Cardiology).
About Prevencio, Inc.
Prevencio's vision is to revolutionize cardiac diagnostics with AI-driven blood tests—thereby improving care with highly accessible, accurate and cost-effective diagnosis and earlier treatment. Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests, genetic risk scores and coronary artery calcium. The company is headquartered in Kirkland, Washington. For additional information, visit Prevencio, Inc.
Forward-Looking (Safe Harbor) Statement:
Except for historical and factual information contained herein, this press release contains forward-looking statements, such as market need, acceptance, and size, the accuracy of which is necessarily subject to various uncertainties of development-stage companies. The company does not undertake to update disclosures contained in this press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Recall issued for potential significant risk with use of Zicam, Orajel swabs. What to know
A "potential microbial contamination" has lead to the recall of several cold nasal swabs and baby teething swabs, according to an announcement from the U.S. Food and Drug Administration June 9. All lots of Zicam Cold Remedy Nasal Swabs, Zicam Nasal AllClear Swabs, and Orajel Baby Teething Swabs have been recalled due to the potential contamination. The swabs can "potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections." Here's what you should know. Church & Dwight Co. is recalling all lots of Zicam Cold Remedy Nasal Swabs, Zicam Nasal AllClear Swabs, and Orajel Baby Teething Swabs due to potential microbial contamination identified as fungi in cotton swab components, according to a June 9 news release. The recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by the recall, the news released from the FDA said. As of June 9, "no serious adverse events" associated with the affected product have been reported, the FDA said. Recalled Zicam and Orajel swabs included in the recall are: Zicam Cold Remedy Nasal Swabs, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam Nasal AllClear Swabs, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel Baby Teething Swabs, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. "Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries. "The risk is highest — potentially severe or life-threatening — among children and individuals with compromised immune systems or other underlying medical conditions." The recalled products were distributed nationwide in the United States and in Puerto Rico. Consumers who have purchased any of the recalled products should stop using the product immediately, the FDA said. Go to or call the Consumer Relations team at 800-981-4710 for a full refund. This article originally appeared on Treasure Coast Newspapers: Zicam recall: cold nasal swabs. Also Orajel baby teething swabs
The Hill
42 minutes ago
- The Hill
Fungal concerns spark nationwide recall of Zicam, Orajel products
(WJW) – Swabs under two well-known brand names have been recalled over potential fungi-related microbial contamination. According to the Food and Drug Administration (FDA), Church & Dwight Co., Inc. is voluntarily recalling some Zicam and Orajel products because fungi could be present in the items' cotton swab components. The recalled products include all lots within expiry of Zicam Cold Remedy Nasal Swabs, Zicam Nasal AllClear Swabs, and Orajel Baby Teething Swabs to the consumer level. Consumers are advised to 'immediately' stop using the recalled products. Major grocery chain slashing prices for the summer 'Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries,' reads the recall alert. 'The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions.' The FDA said, so far, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico, said the FDA. Here are the specific details to check for: Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024). Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. You can view images of the recalled products in the slideshow below: 'This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall,' states the FDA on its website. Consumers can Click here or call (800) 981-4710 for refund details.
Yahoo
an hour ago
- Yahoo
Over 1.7 million eggs sold in 9 states voluntarily recalled due to salmonella concern
More than 1.7 million eggs are being recalled due to potential contamination with salmonella, a type of bacteria that can cause foodborne illness and, in rare cases, even death. August Egg Company is voluntarily recalling brown cage-free and brown organic eggs that were distributed between Feb. 3 and May 15, 2025, in nine states. The Hilmar, California-based company announced the recall Friday, according to an announcement shared on the Food and Drug Administration website. A salmonella outbreak linked to the recalled eggs has already sickened 79 people, with 21 hospitalizations, according to the Centers for Disease Control and Prevention. There have been no reports of deaths so far, the agency stated in a June 6 update. In a statement included in the August Egg Company's recall announcement, the company said, "This recall has been initiated due to possible Salmonella enteritidis contamination, which poses a health risk. With that in mind, we believe it is appropriate out of an abundance of caution to conduct this voluntary recall, as consumers may still have these eggs in their homes." "It is important to know that when our processing plant identified this concern, we immediately began diverting all eggs from the plant to an egg-breaking facility, which pasteurizes the eggs and kills any pathogens," the company continued. "August Egg Company's internal food safety team also is conducting its own stringent review to identify what measures can be established to prevent this situation from recurring. We are committed to addressing this matter fully and to implementing all necessary corrective actions to ensure this does not happen again." FDA elevates tomato recall to highest risk level over potential salmonella contamination The company said it has since voluntarily halted egg distribution, stating in the recall announcement that it "is not selling fresh shell eggs at this time." The recalled eggs have a sell-by date between March 4 and June 4, 2025, and were sold at Food 4 Less, FoodMaxx, Lucky, Raleys, Ralphs, Safeway, Save Mart, and Smart & Final stores in California and Nevada. Additional recalled eggs with a sell-by date between March 4 and June 19, 2025, were sold at Walmart store locations in Arizona, California, Illinois, Indiana, Nebraska, Nevada, New Mexico, Washington and Wyoming. Recalled eggs bear the plant code number P-6562 or CA-5330 with Julian dates between 32 to 126 printed on one side their fiber or plastic cartons or packages. A full list of recalled eggs and photos of their packaging is available on the FDA website. The CDC advises anyone with recalled eggs not to eat them and to discard them or return them to the place of purchase. If recalled eggs came into contact with any surfaces or items, wash the areas with hot, soapy water or a dishwasher. Most people can recover from a salmonella infection after 4 to 7 days without treatment, but an infection can still be serious in certain populations, such as children under 5, pregnant women, older adults over 65 and people with weakened immune systems. Salmonella outbreak linked to cucumbers sold to restaurants sickens 26 people, health officials warn Symptoms of a salmonella infection may include fever, gastrointestinal issues like abdominal pain, diarrhea, stomach cramps, and vomiting, and can appear between six hours and six days after exposure to the bacteria. In rare cases, salmonella travel into the bloodstream and cause more severe illness, such as an infected aneurysm, reactive arthritis or endocarditis, where the inner lining of the heart and valves becomes inflamed. Anyone with symptoms of salmonella should also reach out to a doctor or health care provider if they have diarrhea and a fever higher than 102 degrees Fahrenheit, have had diarrhea for more than three days that is not improving, bloody diarrhea, excessive vomiting or signs of dehydration. Over 1.7 million eggs sold in 9 states voluntarily recalled due to salmonella concern originally appeared on
